Pharmacovigilance Staff Shortage in 2026: Solutions

Updated 15 July 2026.

A shortage of pharmacovigilance professionals creates risks not only for reporting timelines but also for the quality of medicinal-product safety assessment. More data sources, RWD/RWE, digital channels and AI raise the competency requirements for PV teams.

Why pharmacovigilance teams face shortages

• growing product portfolios, country coverage and ICSR volumes;
• roles requiring medical, regulatory, analytical and technology skills;
• competition for QPPVs, medical reviewers, signal and data specialists;
• long development cycles and weak transfer of practical experience;
• burnout caused by deadlines, manual work and uneven workload.

Critical competencies in 2026

Alongside ICSRs, MedDRA, signals, PSUR/PBRER, RMP and PSMF, teams need quality-management, data-analysis, RWD/RWE, vendor-oversight and responsible-automation skills. AI should be used only in a validated environment with data protection, traceability and meaningful human oversight.

How to calculate resource needs

1. Map mandatory processes, products, countries and regulatory deadlines.
2. Forecast cases, literature, signals, aggregate reports and RMP changes.
3. Include medical review, quality control, governance, training, leave and peak demand.
4. Define minimum coverage and back-up for critical roles.
5. Review the forecast quarterly against actual timeliness, errors and overtime.

Practical solutions

• Competency matrix: role requirements, gap assessment and development plans.
• Structured learning: onboarding, case-based practice, mentoring and effectiveness checks.
• Automation: remove duplicate data entry and improve queue prioritisation without delegating medical judgement to a machine.
• Outsourcing: add capacity while retaining oversight, quality metrics, audit rights and MAH responsibility.
• Retention: manageable workload, career paths, task rotation and a transparent quality culture.

What outsourcing must preserve

Agreements should define RACI, data exchange, timelines, quality control, CAPA, training, business continuity, audit rights and exit arrangements. Delegating operations does not remove the marketing authorisation holder’s responsibility for a compliant pharmacovigilance system.

Workforce resilience indicators

• regulatory timeliness and backlog;
• error rate and recurring deviations;
• time to independent competence;
• turnover, overtime and back-up coverage;
• audit, inspection and CAPA outcomes.

PharmExpert supports resource assessments, temporary capacity, competency matrices, training and controlled outsourcing of pharmacovigilance activities.

The resource model should match the organisation’s portfolio, geography and applicable requirements.